SVP, System Chief Medical Officer
Ascension
Pearland, Texas, United States
Thomas Aloia, MD, MHCM, FACS, FACHE, serves as Senior Vice President and Chief Medical Officer for Ascension. He drives standards and strategies for safety and quality, clinical documentation, hospital-based services, procedural areas and clinical technology integration. In collaboration with Ascension’s Strategy team, he pursues service line growth through physician engagement and innovative care design
Dr. Aloia joined Ascension in January 2021 and previously served as Vice President and Director of Oncology Services, Maternal Health and Perinatal Medicine. He has in-depth clinical expertise in hepatobiliary surgery, gastrointestinal surgical oncology, minimally invasive surgery, liver transplantation surgery and functional recovery, as well as administrative acumen in the areas of value based care, service line design, patient safety, and quality.
Dr. Aloia received his medical degree from the University of California – Los Angeles Geffen School of Medicine. His postgraduate training included a general and thoracic surgery residency at Duke University Medical Center and fellowships in Surgical Oncology at MD Anderson and Hepatobiliary Surgery/Liver Transplantation at the Paul Brousse Hospital in Paris, France. He has received a Certificate in Healthcare Management from Rice University Jones Business School and Master’s Degree in Healthcare Management from the Harvard T.H. Chan School of Public Health.
He has published over 250 peer-reviewed manuscripts in the focus areas of surgical outcomes, GI oncology, enhanced recovery and value-based healthcare. He has served as an ad hoc reviewer for multiple medical and surgical journals and is on the editorial board of Annals of Surgery and the Annals of Surgical Oncology.
At MDACC he served multiple administrative roles in the areas of patient safety, quality, and outcomes, including Gastrointestinal Disease Center Medical Director, Executive Director of Network Outcomes, Chief Quality Officer and Head of the Institute for Cancer Care Innovation.
Friday, March 22, 2024
4:00pm – 5:00pm ET